Roche has lifted the lid on the data behind its second phase 3 giredestrant win, linking the oral selective estrogen receptor degrader (SERD) to a 30% reduction in the risk of invasive disease ...

A Chinese biotech helmed by an AstraZeneca veteran has secured $108 million in series B funds, which the company will use to ...

People come to Orlando to escape. With Disney World, SeaWorld and Universal Studios all in the area, there are endless ...

After announcing plans to split up the company near the top of this year, Teleflex said it has found new homes for its ...

The FDA has cleared the first artificial intelligence (AI) drug development tool to help evaluate fatty liver disease in ...

Medline has put forward terms for an absolutely massive IPO, which could see the medical device manufacturing and ...

Exicure’s investigational small molecule succeeded in mobilizing key blood-forming cells in almost 90% of patients in a phase ...

OSE Immunotherapeutics is prioritizing its lung cancer med Tedopi and shifting the strategy for its ulcerative colitis (UC) ...

Pfizer’s recent bidding war for an obesity biotech clearly hasn’t satiated the pharma’s appetite for new GLP-1 therapies—at least going by ...

Novartis is divulging details from ianalumab’s summertime | Novartis is divulging details from ianalumab’s phase 3 win in a rare autoimmune blood disorder, and the data suggest the treatment could del ...

GSK is officially cutting ties with Ideaya Biosciences, handing back two clinical programs as part of the termination of a ...

The FDA is raising the bar for approval of CAR T-cell therapies in oncology. | The FDA is raising the bar for approval of CAR ...